These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

73 related articles for article (PubMed ID: 16227690)

  • 1. Antineoplastic strategy: irreversible tumor blood flow stasis induced by the combretastatin A-4 derivative AVE8062 (AC7700).
    Hori K
    Chemotherapy; 2005 Oct; 51(6):357-60. PubMed ID: 16227690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stoppage of blood flow in 3-methylcholanthrene-induced autochthonous primary tumor due to a novel combretastatin A-4 derivative, AC7700, and its antitumor effect.
    Hori K; Saito S; Sato Y; Kubota K
    Med Sci Monit; 2001; 7(1):26-33. PubMed ID: 11208488
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects due to irreversible stoppage of tumor tissue blood flow: evaluation of a novel combretastatin A-4 derivative, AC7700.
    Hori K; Saito S; Nihei Y; Suzuki M; Sato Y
    Jpn J Cancer Res; 1999 Sep; 90(9):1026-38. PubMed ID: 10551334
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Microvascular mechanisms by which the combretastatin A-4 derivative AC7700 (AVE8062) induces tumour blood flow stasis.
    Hori K; Saito S
    Br J Cancer; 2003 Oct; 89(7):1334-44. PubMed ID: 14520469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of tumour blood flow stasis and necrosis: a new function for epinephrine similar to that of combretastatin A-4 derivative AVE8062 (AC7700).
    Hori K; Saito S
    Br J Cancer; 2004 Jan; 90(2):549-53. PubMed ID: 14735207
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel combretastatin A-4 derivative, AC7700, strongly stanches tumour blood flow and inhibits growth of tumours developing in various tissues and organs.
    Hori K; Saito S; Kubota K
    Br J Cancer; 2002 May; 86(10):1604-14. PubMed ID: 12085211
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential relationship between changes in tumour size and microcirculatory functions induced by therapy with an antivascular drug and with cytotoxic drugs. implications for the evaluation of therapeutic efficacy of AC7700 (AVE8062).
    Hori K; Saito S; Sato Y; Akita H; Kawaguchi T; Sugiyama K; Sato H
    Eur J Cancer; 2003 Sep; 39(13):1957-66. PubMed ID: 12932676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor blood flow interruption after radiotherapy strongly inhibits tumor regrowth.
    Hori K; Furumoto S; Kubota K
    Cancer Sci; 2008 Jul; 99(7):1485-91. PubMed ID: 18452559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Starvation tactics for solid tumors: tumor blood flow interruption via a combretastatin derivative (Cderiv), and its microcirculation mechanism.
    Hori K
    Cancer Metastasis Rev; 2012 Jun; 31(1-2):109-22. PubMed ID: 22101805
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AVE8062: a new combretastatin derivative vascular disrupting agent.
    Delmonte A; Sessa C
    Expert Opin Investig Drugs; 2009 Oct; 18(10):1541-8. PubMed ID: 19758109
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel combretastatin A-4 derivative, AC-7700, shows marked antitumor activity against advanced solid tumors and orthotopically transplanted tumors.
    Nihei Y; Suga Y; Morinaga Y; Ohishi K; Okano A; Ohsumi K; Hatanaka T; Nakagawa R; Tsuji T; Akiyama Y; Saito S; Hori K; Sato Y; Tsuruo T
    Jpn J Cancer Res; 1999 Sep; 90(9):1016-25. PubMed ID: 10551333
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antitumor and antivascular effects of AVE8062 in ovarian carcinoma.
    Kim TJ; Ravoori M; Landen CN; Kamat AA; Han LY; Lu C; Lin YG; Merritt WM; Jennings N; Spannuth WA; Langley R; Gershenson DM; Coleman RL; Kundra V; Sood AK
    Cancer Res; 2007 Oct; 67(19):9337-45. PubMed ID: 17909042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antitumor and antivascular effects of AC-7700, a combretastatin A-4 derivative, against rat liver cancer.
    Ohno T; Kawano K; Sasaki A; Aramaki M; Tahara K; Etoh T; Kitano S
    Int J Clin Oncol; 2002 Jun; 7(3):171-6. PubMed ID: 12109519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
    Cai SX
    Recent Pat Anticancer Drug Discov; 2007 Jan; 2(1):79-101. PubMed ID: 18221055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Advances in the study of the anti-tumor activity of small molecule vascular disrupting agents].
    Cai YC; Zou Y; Xian LJ
    Yao Xue Xue Bao; 2010 Mar; 45(3):283-8. PubMed ID: 21351502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antivascular approaches to solid tumour therapy: evaluation of tubulin binding agents.
    Chaplin DJ; Pettit GR; Parkins CS; Hill SA
    Br J Cancer Suppl; 1996 Jul; 27():S86-8. PubMed ID: 8763854
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevention of cancer recurrence in tumor margins by stopping microcirculation in the tumor and tumor-host interface.
    Hori K; Akita H; Nonaka H; Sumiyoshi A; Taki Y
    Cancer Sci; 2014 Sep; 105(9):1196-204. PubMed ID: 24981848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combretastatin dinitrogen-substituted stilbene analogues as tubulin-binding and vascular-disrupting agents.
    Siles R; Ackley JF; Hadimani MB; Hall JJ; Mugabe BE; Guddneppanavar R; Monk KA; Chapuis JC; Pettit GR; Chaplin DJ; Edvardsen K; Trawick ML; Garner CM; Pinney KG
    J Nat Prod; 2008 Mar; 71(3):313-20. PubMed ID: 18303849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The vascular disrupting agent STA-9584 exhibits potent antitumor activity by selectively targeting microvasculature at both the center and periphery of tumors.
    Foley KP; Zhou D; Borella C; Wu Y; Zhang M; Jiang J; Li H; Sang J; Korbut T; Ye J; Zhang X; Barsoum J; Sonderfan AJ
    J Pharmacol Exp Ther; 2012 Nov; 343(2):529-38. PubMed ID: 22837008
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current development status of small-molecule vascular disrupting agents.
    Chaplin DJ; Horsman MR; Siemann DW
    Curr Opin Investig Drugs; 2006 Jun; 7(6):522-8. PubMed ID: 16784022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.